Advertisement

Herpes Zoster

  • Kenneth Schmader
    Correspondence
    Durham Veterans Affairs Medical Center, 182 GRECC, Durham, NC.
    Affiliations
    Division of Geriatrics, Department of Medicine, Center for the Study of Aging and Human Development, Duke University Medical Center, Box 3003, Durham, NC 27705, USA

    Geriatric Research, Education and Clinical Center (GRECC), Durham Veterans Affairs Medical Center, 182 GRECC, Durham, NC 27705, USA
    Search for articles by this author
Published:April 09, 2016DOI:https://doi.org/10.1016/j.cger.2016.02.011

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Geriatric Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Cohen J.I.
        The varicella-zoster virus genome.
        Curr Top Microbiol Immunol. 2010; 342: 1-14
        • Yawn B.P.
        • Saddier P.
        • Wollan P.C.
        • et al.
        A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction.
        Mayo Clin Proc. 2007; 82: 1341-1349
        • Pinchinat S.
        • Cebrian-Cuenca A.M.
        • Bricout H.
        • et al.
        Similar herpes zoster incidence across Europe: results from a systematic literature review.
        BMC Infect Dis. 2013; 13: 170
        • Oxman M.N.
        • Levin M.J.
        • Johnson G.R.
        • et al.
        • For the Shingles Prevention Study Group
        A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
        N Engl J Med. 2005; 352: 2271-2284
        • Harpaz R.
        • Ortega-Sanchez I.R.
        • Seward J.F.
        • et al.
        • Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC)
        Prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP).
        MMWR Recomm Rep. 2008; 57: 1-30
        • Cohen J.I.
        Herpes zoster.
        N Engl J Med. 2013; 369: 255-263
        • Yawn B.P.
        • Wollan P.C.
        • Kurland M.J.
        • et al.
        Herpes zoster recurrences more frequent than previously reported.
        Mayo Clin Proc. 2011; 86: 88-93
        • Tseng H.F.
        • Chi M.
        • Smith N.
        • et al.
        Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population.
        J Infect Dis. 2012; 206: 190-196
        • Winthrop K.L.
        • Baddley J.W.
        • Chen L.
        • et al.
        Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.
        JAMA. 2013; 309: 887-895
        • Schmader K.E.
        • George L.K.
        • Hamilton J.D.
        Racial differences in the occurrence of herpes zoster.
        J Infect Dis. 1995; 171: 701-705
        • Zhang J.X.
        • Joesoef R.M.
        • Bialek S.
        • et al.
        Association of physical trauma with risk of herpes zoster among Medicare beneficiaries in the United States.
        J Infect Dis. 2013; 207: 1007-1011
        • Hales C.M.
        • Harpaz R.
        • Joesoef M.R.
        • et al.
        Examination of links between herpes zoster incidence and childhood varicella vaccination.
        Ann Intern Med. 2013; 159: 739-745
        • Viner K.
        • Perella D.
        • Lopez A.
        • et al.
        Transmission of varicella zoster virus from individuals with herpes zoster or varicella in school and day care settings.
        J Infect Dis. 2012; 205: 1336-1341
        • Katz J.
        • Cooper E.M.
        • Walther R.R.
        • et al.
        Acute pain in herpes zoster and its impact on health-related quality of life.
        Clin Infect Dis. 2004; 39: 342-348
        • Schmader K.E.
        • Sloane R.
        • Pieper C.
        • et al.
        The impact of acute herpes zoster pain and discomfort on functional status and quality of life in older adults.
        Clin J Pain. 2007; 23: 490-497
        • Jung B.F.
        • Johnson R.W.
        • Griffin D.R.
        • et al.
        Risk factors for postherpetic neuralgia in patients with herpes zoster.
        Neurology. 2004; 62: 1545-1551
        • Harbecke R.
        • Oxman M.N.
        • Arnold B.A.
        • et al.
        A real-time PCR assay to identify and discriminate among wild-type and vaccine strains of varicella-zoster virus and herpes simplex virus in clinical specimens, and comparison with the clinical diagnoses.
        J Med Virol. 2009; 81: 1310-1322
        • Dworkin R.H.
        • Johnson R.W.
        • Breuer J.
        • et al.
        Recommendations for the management of herpes zoster.
        Clin Infect Dis. 2007; 44: S1-S26
        • Dworkin R.H.
        • Barbano R.L.
        • Tyring S.K.
        • et al.
        A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster.
        Pain. 2009; 142: 209-217
        • Esmann V.
        • Geil J.P.
        • Kroon S.
        • et al.
        Prednisolone does not prevent postherpetic neuralgia.
        Lancet. 1987; 2: 126-129
        • Wood M.J.
        • Johnson R.W.
        • McKendrick M.W.
        • et al.
        A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster.
        N Engl J Med. 1994; 330: 896-900
        • Whitley R.J.
        • Weiss H.
        • Gnann J.W.
        • et al.
        Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial.
        Ann Intern Med. 1996; 125: 376-383
        • Berry J.D.
        • Petersen K.L.
        A single dose of gabapentin reduces acute pain and allodynia in patients with herpes zoster.
        Neurology. 2005; 65: 444-447
        • van Wijck A.J.M.
        • Opstelten W.
        • Moons K.G.
        • et al.
        The PINE study of epidural steroids and local anaesthetics to prevent postherpetic neuralgia: a randomised controlled trial.
        Lancet. 2006; 367: 219-224
        • Johnson R.W.
        • Rice A.S.
        Postherpetic neuralgia.
        N Engl J Med. 2014; 371: 1526-1533
        • NICE clinical guideline 173
        Neuropathic pain—pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings.
        National Institute for Health and Care Excellence, London2013 (Available at: http://guidance.nice.org.uk/CG173)
        • Dworkin R.H.
        • O’Connor A.B.
        • Audette J.
        • et al.
        Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.
        Mayo Clin Proc. 2010; 85: S3-S14
        • Watson C.P.N.
        • Vernich L.
        • Chipman M.
        • et al.
        Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial.
        Neurology. 1998; 51: 1166-1171
        • Raja S.N.
        • Haythornthwaite J.A.
        • Pappagallo M.
        • et al.
        Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial.
        Neurology. 2002; 59: 1015-1021
        • Gilron I.
        • Bailey J.M.
        • Tu D.
        • et al.
        Morphine, gabapentin, or their combination for neuropathic pain.
        N Engl J Med. 2005; 352: 1324-1334
        • Gilron I.
        • Bailey J.M.
        • Tu D.
        • et al.
        Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial.
        Lancet. 2009; 374: 1252-1261
        • Weiner D.K.
        • Schmader K.E.
        Postherpetic pain: more than sensory neuralgia?.
        Pain Med. 2006; 7: 243-249
        • Tseng H.F.
        • Smith N.
        • Harpaz R.
        • et al.
        Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease.
        JAMA. 2011; 305: 160-166
        • Langan S.M.
        • Smeeth L.
        • Margolis D.
        • et al.
        Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study.
        PLoS Med. 2013; 10: e1001420
        • Schmader K.E.
        • Johnson G.R.
        • Saddier P.
        • et al.
        Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality of life measures in older adults.
        J Am Geriatr Soc. 2010; 58: 1634-1641
        • Tseng H.F.
        • Tartof S.
        • Harpaz R.
        • et al.
        Vaccination against zoster remains effective in older adults who later undergo chemotherapy.
        Clin Infect Dis. 2014; 59: 913-919
        • Simberkoff M.S.
        • Arbeit R.D.
        • Johnson G.R.
        • et al.
        • For the Shingles Prevention Study Group
        Safety of the herpes zoster vaccine in the Shingles Prevention Study: a randomized trial.
        Ann Intern Med. 2010; 152: 545-554
        • Tseng H.F.
        • Liu A.
        • Sy L.
        • et al.
        Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study.
        J Intern Med. 2012; 271: 510-520
        • Schmader K.E.
        • Oxman M.N.
        • Levin M.J.
        • et al.
        • For the Shingles Prevention Study Group
        Persistence of the efficacy of zoster vaccine in the shingles prevention study and the short-term persistence substudy.
        Clin Infect Dis. 2012; 55: 1320-1328
        • Morrison V.A.
        • Oxman M.N.
        • Johnson G.
        • et al.
        Long-term persistence of zoster vaccine efficacy.
        Clin Infect Dis. 2015; 60: 900-909
        • Schmader K.E.
        • Levin M.J.
        • Gnann J.W.
        • et al.
        Efficacy, safety, tolerability of herpes zoster vaccine in persons 50-59 years of age.
        Clin Infect Dis. 2012; 54: 922-928
        • Hales C.M.
        • Harpaz R.
        • Ortega-Sanchez I.
        • et al.
        Update on recommendations for use of herpes zoster vaccine.
        MMWR Morb Mortal Wkly Rep. 2014; 63: 729-731
        • Lal H.
        • Cunningham A.L.
        • Godeaux O.
        • et al.
        Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults.
        N Engl J Med. 2015; 372: 2087-2096